Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Pan, Long; Fang, Jing; Tong, Chenhao; Chen, Mingyu; Zhang, Bin; Juengpanich, Sarun; Wang, Yifan; Cai, Xiujun

doi:10.1186/s12957-019-1767-5

Table 2 Summary of Clinicopathological characteristics of the eligible studies

From: Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Study	Patients factor		Tumor factor				AT, %	Matched factor^a
Study	No. of participants (female, %)	Age, mean (SD), y	Size, mean (SD), cm	Site (head, %)	VR, %	CA19-9, mean (SD), U/ml	AT, %	Matched factor^a
Barbier et al. [23]	NAT: 88 SF:85	65 (39–81)^g 64 (37–79)	NA	100 100	16 30	> 350 (16)^b > 350 (15)	0 NA	1, 4, 5, 6
Papalezova et al. [24]	NAT: 144 (46) SF: 92 (47)	64 (12) 65 (12)	2.5 (1.2) 2.1 (1.3)	100 100	18 22	NA	33 66	1, 2, 4, 5
Tajima et al. [25]	NAT: 13 (46) SF: 21 (33)	63 (51–77)^g 66 (52–80)	NA	69 52	100 100	NA	NA	1, 2, 4, 5
Cho et al. [26]	NAT: 30 (47) SF: 21 (52)	59.57 (8.6) 60.76 (10.8)	2.6 (0.9) 2.6 (0.8)	87 86	43 38	1189 (2482) 540 (840)	50 62	1, 2, 3, 4, 5, 6, 7
Jiang et al. [27]	NAT: 112 (33) SF: 120 (43)	45.9 (9.8) 45.5 (9.3)	NA	88 80	NA	211 (46) 284 (56)	0 0	1, 2, 4, 6, 7
Patel et al. [28]	NAT: 17 (47) SF: 13 (31)	60 (39–72)^g 71 (42–82)	NA	88 85	NA	NA	82 77	1, 2, 4, 7
Roland et al. [30]	NAT: 222 (44) SF: 85 (40)	64 (35–86)^g 64 (40–85)	NA	92 87	31 27	< 1000 (74)^b < 1000 (66)	11 68	1, 2, 4, 5, 6
Lee et al. [29]	NAT: 30 (60) SF: 28 (50)	61.7 (8.8) 62.9 (9.6)	2.7(0.7) 2.6(0.7)	90 96	70 29	816 (1452) 504 (830)	73 75	1, 2, 3, 6, 7
Sho et al. [31]^c	NAT: 85 (45) SF: 99 (47)	65.7 (8.9) 68.9 (10)	NA	NA	NA	NA	61 48	2, 7
Golcher et al. [36]	NAT: 33 (45) SF: 33 (48)	62.5 (33–76) 65.1 (46–73)	NA	100 100	NA 22	NA	37 30	1, 2, 4, 7
Hirono et al. [32]	NAT: 46 SF: 124	69 (41–90)^g	3 (1.1–7.1)^g 2.9 (1.2–8.5)	43 56	60 42	NA	53 64	3, 4, 5, 7
Masui et al. [33]	NAT: 18 (56) SF: 19 (68)	63 (43–73)^g 66 (56–80)	3.3 (1.8–5)^g 3.2 (1.7–7.5)	72 68	47 37	102 217	78 84	1, 2, 3, 4, 5, 6, 7
Ielpo et al. [3]^d	NAT: 45 (36) SF: 36 (42)	62 (42–81)^f 64 (46–78)	7.5 6.8	71 58	35 36	1754 1621	61 58	1, 2, 3, 4, 5, 6, 7
Murakami et al	NAT: 52 (33) SF: 25 (28)	> 67 (48)^b > 67 (60)	≥ 37 (52)^b ≥ 37 (34)	67 84	62 57	> 150 (52)^b > 150 (52)	80 48	1, 2, 4, 6
Fujii et al. [34]^e	NAT: 40 (48) SF: 233 (37)	65 (36–79)^g 67 (35–88)	2.9 (1.5–5.2)^g 2.5 (0.8–5.6)	100 100	25 32	143 148	67 66	1,2,3,4,5,6,7
	NAT: 27 (56) SF: 102 (48)	68 (47–78)^g 66 (39–83)	3 (1.8–3.9)^g 3.3 (1.5–7)	100 100	96 95	323 259	39 44	1, 2, 3, 4, 5, 6, 7
	NAT: 21 (52) SF: 81 (37)	68 (47–76)^g 65 (42–82)	3.5 (2.6–4.6)^g 3 (2–6)	100 100	79 87	286 218	46 43	1, 2, 3, 4, 5, 6, 7
Jang et al. [9]	NAT: 27 (37) SF: 23 (35)	59.4 (8.4) 58.9 (11.3)	3.4 (0.8) 3.5 (0.9)	85 74	35 28	1042 (2465) 1258 (2540)	52 57	1, 2, 3, 4, 5, 6, 7
Reni et al. [12]	NAT: 32 (22) SF: 26 (46)	64 (39–75)^g 65 (37–74)	2.0 (0–6.0)^g 2.5 (1.5–5.0)	88 96	0 9	173 (43–4510) 179 (39–3337)	72 65	1, 2, 3, 4, 5, 6, 7

Abbreviations: NAT neoadjuvant therapy, SF surgery first, AT adjuvant therapy, VR vascular resection, NA not available
^aFactors matched with NAT and SF: 1, age; 2, sex; 3, initial tumor size; 4, tumor location; 5, vascular resection; 6, initial CA19-9 level; 7, AT
^bReported as range (percentage, %)
^cThe study by Sho et al. has 2 independent data sets (1 data set for RPC and 1 data set for BRPC)
^dThe study by lelpo et al. has 1 data set for RPC/BRPC, but it has 2 data subsets (1 data subset for RPC and 1 data subset for BRPC)
^eThe study by Fujii et al. has 3 independent data sets (1 data set for RPC, 1 data set for BRPC, and 1 data set for RPC/BRPC)
^fReported as mean (range)
^gReported as median (range)

Back to article page

ISSN: 1477-7819

Contact us

Submission enquiries: reginald.medina@springernature.com
General enquiries: info@biomedcentral.com

World Journal of Surgical Oncology

Contact us